Enem Nostrum Remedies Profile
Key Indicators
- Authorised Capital ₹ 4.35 Cr
as on 23-10-2024
- Paid Up Capital ₹ 2.35 Cr
as on 23-10-2024
- Company Age 23 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 40.62 Cr
as on 23-10-2024
- Satisfied Charges ₹ 104.21 Cr
as on 23-10-2024
- Revenue 2.28%
(FY 2023)
- Profit -38.48%
(FY 2023)
- Ebitda 15.80%
(FY 2023)
- Net Worth 1.79%
(FY 2023)
- Total Assets 14.27%
(FY 2023)
About Enem Nostrum Remedies
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 4.35 Cr and a paid-up capital of Rs 2.35 Cr.
The company currently has active open charges totaling ₹40.62 Cr. The company has closed loans amounting to ₹104.21 Cr, as per Ministry of Corporate Affairs (MCA) records.
Shraddha Dhamankar, Nirmal Mulye, and Anilkumar Mulye serve as directors at the Company.
- CIN/LLPIN
U24229MH2001PTC130260
- Company No.
130260
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
01 Jan 2001
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Enem Nostrum Remedies Private Limited offer?
Enem Nostrum Remedies Private Limited offers a wide range of products and services, including Medical Consultants & Clinics, Medical Consultancy Services, Pharma & Bioanalytical Services, Pharmaceutical Services, Research and Development (R&D) Work, Product Development Research, Company Law & Labour Law Consultants, Statutory Compliance Services, Analyzers & Analytical Instruments, Chromatographic Analyzer.
Who are the key members and board of directors at Enem Nostrum Remedies?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nirmal Mulye  | Director | 14-Aug-2001 | Current |
Shraddha Dhamankar  | Director | 01-Jan-2001 | Current |
| Anilkumar Mulye | Additional Director | 18-Sep-2024 | Current |
Financial Performance and Corporate Structure Insights of Enem Nostrum Remedies.
Enem Nostrum Remedies Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 2.28% increase. The company also saw a substantial fall in profitability, with a 38.48% decrease in profit. The company's net worth moved up by a moderate rise of 1.79%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Enem Nostrum Remedies?
In 2023, Enem Nostrum Remedies had a promoter holding of 99.99%. The company had 6 Subsidiaries and 1 Associate company. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Nexgen Healthcare Private LimitedActive 20 years 3 monthsShraddha Dhamankar and Anilkumar Mulye are mutual person
Nli Healthcare (India) Private LimitedActive 5 years 10 monthsShraddha Dhamankar and Nirmal Mulye are mutual person
Symmetrix Biotech Private LimitedActive 17 years 10 monthsShraddha Dhamankar and Nirmal Mulye are mutual person
- Nostrum Technologies Private LimitedActive 17 years 3 months
Shraddha Dhamankar and Nirmal Mulye are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Bank Of India Creation Date: 05 Dec 2022 | ₹37.11 Cr | Open |
Others Creation Date: 11 Mar 2022 | ₹4.77 M | Open |
Others Creation Date: 04 Mar 2022 | ₹4.77 M | Open |
How Many Employees Work at Enem Nostrum Remedies?
Enem Nostrum Remedies has a workforce of 143 employees as of Mar 26, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Enem Nostrum Remedies, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Enem Nostrum Remedies's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
